Key terms
About ARTL
Artelo Biosciences, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system. Its product candidate pipeline includes ART27.13-Synthetic Cannabinoid Agonist, ART26.12-FABP5 inhibitor, and ART12.11-Synthetic CBD Cocrystal. The company was founded on May 2, 2011 and is headquartered in Solana Beach, CA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest ARTL news
Apr 02
10:30am ET
Wall Street Analysts Are Bullish on Top Healthcare Picks
Mar 26
6:45am ET
Buy Rating on Artelo Biosciences: Strong Pipeline and Market Potential
Mar 25
8:04am ET
Artelo Biosciences reports 2023 EPS ($3.14), consensus ($2.56)
Mar 04
4:32pm ET
Artelo Biosciences Revises Stock Options for Employee Retention
Jan 23
8:32am ET
Artelo Biosciences announces publication on research on ART26.12
Jan 08
8:49am ET
Artelo Biosciences selects Worldwide Clinical Trials as CRO
No recent news articles are available for ARTL
ARTL Financials
Key terms
Ad Feedback
ARTL Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
ARTL Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
